London-based lab automation company Automata has closed a $45 mn Series C round led by Dimension, with participation from Danaher Ventures and a strategic investment partnership with Danaher Corporation.
The capital will support global deployment of Automata’s LINQ platform, which combines modular robotics with orchestration software aimed at making wet laboratories programmable and compatible with AI-driven experimentation.
As part of the transaction, Murali Venkatesan, Global Head of Danaher Ventures and VP of Science, Technology and Innovation, joins Automata’s board.
The partnership will integrate technologies from Danaher subsidiaries including Molecular Devices and Beckman Coulter Life Sciences into the LINQ ecosystem, extending coverage across liquid handling, genomic workflows and cell analysis.
Automata reports five top pharmaceutical companies among its customers, with repeat deployments driving expansion.
Chief executive Mostafa Elsayed described LINQ as an operating layer between AI models and laboratory hardware, allowing scientists to program experiments at a systems level rather than managing individual robotic actions.
Proceeds will fund international customer rollouts, development of closed-loop experimentation software and growth across engineering, product and customer success teams.
The round also included Tru Arrow Partners, Octopus Ventures and Entrepreneurs First.
Competition is intensifying around lab orchestration software, which coordinates instruments, schedules workflows and feeds experimental data into AI systems.
The partnership with Danaher provides distribution and integration reach, though it closely aligns LINQ with Danaher’s instrument portfolio.
Beckman Coulter Life Sciences separately confirmed the integration of its liquid handling and genomic technologies with Automata’s platform.
